<DOC>
	<DOCNO>NCT00662818</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy telcagepant treatment acute migraine participant stable vascular disease . Acetaminophen/paracetamol ( APAP ) use active comparator study . The primary hypothesis study telcagepant 300 mg superior placebo .</brief_summary>
	<brief_title>Telcagepant ( MK-0974 ) Treatment Migraine Participants With Stable Vascular Disease ( MK-0974-034 )</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Stable coronary artery disease 3 month 18 year age old history migraine without aura Must use acceptable contraception throughout study Pregnant , breastfeeding , plan become pregnant study 50 year age old migraine begin Other pain syndrome might interfere study assessment , uncontrolled psychiatric condition , dementia , significant neurological disorder ( migraine ) History gastric , small intestinal surgery , disease cause malabsorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>